Menelas N. Pangalos
From Wikipedia, the free encyclopedia
 |
This article or section needs to be wikified to meet Wikipedia's quality standards. Please help improve this article with relevant internal links. (March 2008) |
 |
This article does not cite any references or sources. (March 2008) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
Menelas Pangalos Ph.D. (born 1967 in Ealing, London) is a British-born Neuroscientist of Chios, Greece decent. He is best known for his work on the discovery and development of novel drugs to treat Alzheimer’s disease, and was recently listed as an “R&D Difference-Maker” by R&D Directions magazine, for his efforts in the field of Alzheimer’s drug discovery. He is the author of over 100 publications in scientific journals.
Menelas Pangalos commenced his scientific career with an undergraduate degree in Biochemistry from the Imperial College of Science and Technology, London and a subsequent Ph.D. in Neurochemistry from the Institute of Neurology, London. His post-doctoral training was conducted under the tutelage of Prof. N.K. Robakis at the Mount Sinai Medical Center, New York.
Currently Menelas Pangalos is the Vice President of Neuroscience Research at Wyeth, a leading pharmaceutical company. In this role, which he has held since 2003, he has been responsible for overseeing the transition of more than 20 novel drug candidates into clinical development for a number of devastating neurological and psychiatric diseases such as Alzheimer’s disease, Stroke, Schizophrenia, and Pain. He previously served as Group Director and Head of Neurodegenerative Research at GlaxoSmithKline in Harlow, United Kingdom, and has held positions with SmithKline Beecham, Janssen Pharmaceutica and Bristol-Myers Squibb.
Menelas Pangalos is an Adjunct Professor of Neuroscience at the University of Pennsylvania and a Visiting Professor at King’s College London. He is on the editorial boards of Molecular and Cellular Neuroscience and The Scientific World and on scientific advisory boards for the Wolfson Centre for Age Related Diseases (King’s College London University) and Rider University. He has previously served on the BBSRC Molecular and Cell Biology council and is a member of the American Society for Neuroscience, British Pharmacological Society and an Associate of the Royal College of Science. Dr. Pangalos has edited the book “Understanding G-protein coupled receptors in the CNS”, as well as a number of journal issues focused on drug discovery in the CNS.
